Donald C Simonson1,2, Bo Hu3, David E Arterburn4, Philip R Schauer5, Sangeeta R Kashyap3, Anita P Courcoulas6, David E Cummings7, Mary-Elizabeth Patti2,8, William F Gourash6, Ashley H Vernon1,2, John M Jakicic9, John P Kirwan5. 1. Brigham and Women's Hospital, Boston, Massachusetts, USA. 2. Harvard Medical School, Boston, Massachusetts, USA. 3. Cleveland Clinic, Cleveland, Ohio, USA. 4. Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA. 5. Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA. 6. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 7. University of Washington Medical School, Seattle, Washington, USA. 8. Joslin Diabetes Center, Boston, Massachusetts, USA. 9. AdventHealth Research Institute, Orlando, Florida, USA.
Abstract
AIMS: Long-term data from randomized clinical trials comparing metabolic (bariatric) surgery versus a medical/lifestyle intervention for treatment of patients with obesity/overweight and type 2 diabetes (T2D) are lacking. The Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) is a consortium of four randomized trials designed to compare long-term efficacy and safety of surgery versus medical/lifestyle therapy on diabetes control and clinical outcomes. MATERIALS AND METHODS: Patients with T2D and body mass index (BMI) of 27-45 kg/m2 who were previously randomized to metabolic surgery (Roux-en-Y gastric bypass, adjustable gastric band, or sleeve gastrectomy) versus medical/lifestyle intervention in the STAMPEDE, SLIMM-T2D, TRIABETES, or CROSSROADS trials have been enrolled in ARMMS-T2D for observational follow-up. The primary outcome is change in glycated haemoglobin after a minimum 7 years of follow-up, with additional analyses to determine rates of diabetes remission and relapse, as well as cardiovascular and renal endpoints. RESULTS: In total, 302 patients (192 surgical, 110 medical/lifestyle) previously randomized in the four parent studies were eligible for participation in the ARMMS-T2D observational study. Participant demographics were 71% white, 27% African-American and 68% female. At baseline: age, 50 ± 8 years; BMI, 36.5 ± 3.5 kg/m2 ; duration of diabetes, 8.8 ± 5.6 years; glycated haemoglobin, 8.6% ± 1.6%; and fasting glucose, 168 ± 64 mg/dl. More than 35% of patients had a BMI <35 kg/m2 . CONCLUSIONS: ARMMS-T2D will provide the largest body of long-term, level 1 evidence to inform clinical decision-making regarding the comparative durability, efficacy and safety of metabolic surgery relative to a medical/lifestyle intervention among patients with T2D, including those with milder class I obesity or mere overweight.
AIMS: Long-term data from randomized clinical trials comparing metabolic (bariatric) surgery versus a medical/lifestyle intervention for treatment of patients with obesity/overweight and type 2 diabetes (T2D) are lacking. The Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) is a consortium of four randomized trials designed to compare long-term efficacy and safety of surgery versus medical/lifestyle therapy on diabetes control and clinical outcomes. MATERIALS AND METHODS: Patients with T2D and body mass index (BMI) of 27-45 kg/m2 who were previously randomized to metabolic surgery (Roux-en-Y gastric bypass, adjustable gastric band, or sleeve gastrectomy) versus medical/lifestyle intervention in the STAMPEDE, SLIMM-T2D, TRIABETES, or CROSSROADS trials have been enrolled in ARMMS-T2D for observational follow-up. The primary outcome is change in glycated haemoglobin after a minimum 7 years of follow-up, with additional analyses to determine rates of diabetes remission and relapse, as well as cardiovascular and renal endpoints. RESULTS: In total, 302 patients (192 surgical, 110 medical/lifestyle) previously randomized in the four parent studies were eligible for participation in the ARMMS-T2D observational study. Participant demographics were 71% white, 27% African-American and 68% female. At baseline: age, 50 ± 8 years; BMI, 36.5 ± 3.5 kg/m2 ; duration of diabetes, 8.8 ± 5.6 years; glycated haemoglobin, 8.6% ± 1.6%; and fasting glucose, 168 ± 64 mg/dl. More than 35% of patients had a BMI <35 kg/m2 . CONCLUSIONS: ARMMS-T2D will provide the largest body of long-term, level 1 evidence to inform clinical decision-making regarding the comparative durability, efficacy and safety of metabolic surgery relative to a medical/lifestyle intervention among patients with T2D, including those with milder class I obesity or mere overweight.
Authors: Steven H Belle; Sara J Czaja; Richard Schulz; Song Zhang; Louis D Burgio; Laura N Gitlin; Richard Jones; Aaron B Mendelsohn; Marcia G Ory Journal: Psychol Aging Date: 2003-09
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Ali Aminian; Stacy A Brethauer; Sankar D Navaneethan; Rishi P Singh; Claire E Pothier; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: David Arterburn; David R Flum; Emily O Westbrook; Sharon Fuller; Mary Shea; Steven N Bock; Jeffrey Landers; Katie Kowalski; Emily Turnbull; David E Cummings Journal: Surg Obes Relat Dis Date: 2013-06-04 Impact factor: 4.734
Authors: Francesco Rubino; David M Nathan; Robert H Eckel; Philip R Schauer; K George M M Alberti; Paul Z Zimmet; Stefano Del Prato; Linong Ji; Shaukat M Sadikot; William H Herman; Stephanie A Amiel; Lee M Kaplan; Gaspar Taroncher-Oldenburg; David E Cummings Journal: Diabetes Care Date: 2016-06 Impact factor: 19.112
Authors: Nicholas L Syn; David E Cummings; Louis Z Wang; Daryl J Lin; Joseph J Zhao; Marie Loh; Zong Jie Koh; Claire Alexandra Chew; Ying Ern Loo; Bee Choo Tai; Guowei Kim; Jimmy Bok-Yan So; Lee M Kaplan; John B Dixon; Asim Shabbir Journal: Lancet Date: 2021-05-06 Impact factor: 79.321
Authors: Jonathan Q Purnell; Faith Selzer; Abdus S Wahed; John Pender; Walter Pories; Alfons Pomp; Greg Dakin; James Mitchell; Luis Garcia; Myrlene A Staten; Carol McCloskey; David E Cummings; David R Flum; Anita Courcoulas; Bruce M Wolfe Journal: Diabetes Care Date: 2016-07 Impact factor: 19.112